EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

Christian A Engell, Vinh Philip Pham, Robert S Holzman, Judith A Aberg

ISRN Gastroenterology · 2011

DOI: 10.5402/2011/405390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Gastroenterology, 2011. Verfasst von Christian A Engell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and Immunology, New York University School of Medicine at Bellevue Hospital Center, New York,…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Goal . To study the effect of combination antiviral therapy with tenofovir and emtricitabine or lamivudine with and without prior monotherapy with lamivudine. Study . We reviewed charts of 31 HIV-/HBV-coinfected patients. Twelve 3TC-naïve patients initially received tenofovir plus emtricitabine. Nineteen epivir experienced patients who had previously failed epivir were given tenofovir plus emtricitabine.

Results

Baseline median HBV DNA was similar in the epivir-naïve (5 . 8 × 10 7 copies/mL) and experienced group (7 . 3 × 10 7 copies/mL, P = . 65 ). The median time to complete suppression of HBV was 466 days in the naïve group and 877 days in the experienced ( P = . 001 ). After 12 months, 6/10 (60%) naïve patients and 3/14 (21%) experienced patients had HBV DNA below the detectionlimit ( P = . 067 ). After 24 months, 5/5 (100%) naïve patients and 4/13 (31%) experienced patients had an undetectable HBV DNA level ( P = . 015 ).

Conclusions

The median time to suppression of HBV DNA was significantly shorter among treatment naïve patients. There was a significantly greater proportion of naïve patients with suppressed HBV DNA at 24 months. Our results support using initial dual therapy in those with HIV/HBV coinfection.

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases and Immunology, New York University School of Medicine at Bellevue Hospital Center, New York, NY 10016, USA.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Engell, C. A., Pham, V. P., Holzman, R. S., & Aberg, J. A. (2011). Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterology. https://doi.org/10.5402/2011/405390

Vancouver

Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterology. 2011. doi:10.5402/2011/405390

BibTeX
@article{Engell2011,
  author = {Engell, Christian A and Pham, Vinh Philip and Holzman, Robert S and Aberg, Judith A},
  title = {Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients},
  journal = {ISRN Gastroenterology},
  year = {2011},
  doi = {10.5402/2011/405390}
}
Kostenlos starten →